Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Karo Bio has reacquired the full rights to selective androgen receptor modulators or SARMs that were licensed to Radius in September 2006 agreement.
Subscribe to our email newsletter
The SARM compounds were in-licensed by Radius with the intention to develop new compounds for treatment of osteoporosis. Karo Bio has now reacquired all rights to the SARM compounds and to related data generated by Radius.
Per Olof Wallstrom, president of Karo Bio, said: “There are several therapeutic opportunities for compounds targeting the androgen receptor, and the retained rights and data to the SARMs add value to our technology base.”